TNGX ▲ +11.9% - Tango Therapeutics, Inc.
$TNGX - Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy
23-OCT-2026 06:30 AM ET
Share this post
More filings for $TNGX
TNGX ▲ +0.6% - Tango Therapeutics, Inc.Oct 16, 2026TNGX ▲ +2.1% - Tango Therapeutics, Inc.Sep 3, 2026TNGX ▼ -1.3% - Tango Therapeutics, Inc.Sep 1, 2026TNGX - Tango Therapeutics, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 15, 2026TNGX - Tango Therapeutics, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026TNGX - Tango Therapeutics, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026
View full $TNGX filing history →💬 Comments
Loading comments…
Leave a comment